Novel Use of GnRH agonist as Neoadjuvant Treatment for Giant Endometrial Polyps*

Diana J. Cupino-Arcinue, MD and Ma. Regina Paz Tan-Espiritu, MD, FPOGS, FPSRM, FPSGE Section of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Philippine General Hospital, University of the Philippines Manila

Endometrial polyp, being one of the most common causes of abnormal uterine bleeding, is formed from localized overgrowths of endometrial tissue brought about by increased estrogen levels. Sizes of polyps usually are less than 2cm, while those >4 cm are labeled as giant polyps. Such polyps can even occupy the entire endometrial cavity, making complete hysteroscopic removal difficult and prone to failure and morbidity. Limited literature regarding use of GnRH agonist in endometrial polyps are published, but given the idea that it induces a state of hypoestrogenism, it could be a promising approach for neoadjuvant treatment in such cases. In this paper, 3 cases of giant endometrial polyps with fertility problems were given GnRH agonists prior to resection. All cases have shown significant decrease in size of their polyps, making complete and successful hysteroscopic removal feasible.

Keywords: Giant endometrial polyp, GnRH agonist, hysteroscopic removal

Introduction

Endometrial polyp is one of the most common structural causes of abnormal uterine bleeding in the reproductive age group. It arises from endometrial overgrowth brought about by a hyperestrogenic state. Polyps are usually around 2cm in size, and those greater than 4cm are labeled as giant polyps. The cases presented are women in the reproductive age group with fertility problems, having endometrial polyps as large as 10cm occupying the whole uterine cavity, even prolapsing out of the endocervical canal. Conservative management was recommended but due to their size, immediate hysteroscopic removal may not be attainable due to expected difficulty in distending the uterine cavity and possible morbidities like fluid overload and uterine

perforation. Although with limited studies, GnRH agonists have been proposed as a neoadjuvant treatment prior to hysteroscopic removal of giant polyps. Given the same mechanism applied with GnRH agonist's use with myomas, it induces a hypoestrogenic environment at the same time decreasing the vascularity of the endometrial lining that will help significantly decrease the size of the giant polyps, making hysteroscopic removal feasible.

The Case

Case #1

This is a case of abnormal uterine bleeding in a 29-year-old, single, nulligravid from Laguna. The patient has unremarkable past medical and family history. She is living in with her 3-year partner and is desirous of pregnancy.

^{*}First Place, Poster Contest 2018 PSRM Annual Convention

Since menarche, patient has been experiencing heavy menstrual bleeding, soaking 2-3 baby diapers per day, lasting 7-14 days, with no associated symptoms. She was hospitalized at the age of 16 for blood transfusion due to chronic blood loss brought about by heavy menstrual bleeding. Blood dyscrasia was ruled out. At the age of 20, she consulted a government hospital still for persistent heavy menstrual bleeding now associated with dyspareunia and post-coital vaginal bleeding. She was assessed with a cervical mass probably polyp and underwent fractional curettage and polypectomy, which on biopsy revealed polyp. At the age of 22, she again consulted the same institution for the same complaint and diagnosis. Repeat fractional curettage and polypectomy was done and biopsy again revealed polyp. Patient still had occasional heavy menstrual bleeding however few months prior to consult in our institution, she had continuous profuse vaginal bleeding, this time associated with an enlarging abdomino-pelvic mass extending to the infraumbilical region. No constitutional symptoms were noted. She was assessed from the same hospital with cervical cancer due to a finding of irregularly-shaped cervical mass. A cervical punch biopsy was done which only revealed granulation tissue. She was then referred to our institution for further work up and management.

When we first saw the patient, she was pale but with stable vital signs. Speculum examination revealed a polypoid fleshy mass occupying the upper half of the vaginal canal. On internal examination, patient had normal external genitalia, lower half of the vagina was smooth and there was a polypoid fleshy mass measuring 8 cm x 10 cm x 10 cm occupying the upper vaginal canal. The corpus was enlarged to 18-20 weeks size. Rectovaginal examination was unremarkable.

She was initially diagnosed as a case of cervical cancer and was admitted for blood transfusion and work up. Cervical punch biopsy was repeated in our institution and it revealed necrotic and hemorrhagic polypoid lesion. Transvaginal ultrasound done noted an aggregate of polyps at the cervix that arise from the endometrial cavity with attachment at the fundus. Impression was endometrial mass, to consider endometrial pathology with extension to less than 50% of the myometrium, endocervical canal, and lower third of vagina (Figure 1). Current working diagnosis was changed to abnormal uterine bleeding secondary to endometrial mass probably endometrial polyp.




Figure 1. Endometrial mass and prolapsing cervical mass arising from the endometrium prior to GnRH agonist.

Patient was referred to our section for possible hysteroscopic polypectomy. But due to the size of the mass and expected technical difficulty for hysteroscopic removal, we advised pre-treatment with Gonadotropin-Releasing Hormone (GnRH) agonist to be given for 3 to 6 doses every 28 days prior to surgery.

After three doses of GnRH, repeat internal examination showed that the polypoid mass at the cervix disintegrated and was easily removed from its attachment. Patient noted minimal vaginal bleeding with passage of meat-like material, probably fragments of the polyp. The corpus size also decreased to 14 to 16 weeks size, from the initial 18-20 weeks size. Additional 3 doses of GnRH agonist were suggested to further decrease the size of the mass and make the hysteroscopy easier.

After 6 doses of GnRH agonists with a corpus size of 10-12 weeks, the patient then underwent hysteroscopic polypectomy. Intraoperatively, the polypoid mass was soft and hemorrhagic, but was not friable and non-necrotic, with an aggregate diameter of 17 cm (Figures 2 & 3). Cut section revealed multiple cystic spaces all throughout the mass. Final biopsy report showed mixed endocervical-endometrial polyp. Three months post-surgery, there was no recurrence of heavy menstrual bleeding and repeat ultrasound revealed normal uterus with thin endometrium (Figure 4). Currently, the patient is already 1 year post op with no recurrence of the heavy menstrual bleeding, and is currently for infertility management.



Figure 2. The intraoperative picture of the prolapsing cervical mass.



Figure 3. The endometrial polyp removed by vaginal polypectomy with hysteroscopic resection of pedicle.






Figure 4. Post operative ultrasound of patient 3 months after.

Case 2

This is another case of abnormal uterine bleeding in a 30-year-old, Gravida 2 Para 0 (0020), married, from Mindoro. The patient has unremarkable past medical, family and menstrual history. She had 2 previous pregnancies that both ended up in spontaneous abortions at 12 weeks AOG wherein she both underwent dilatation and curettage. She is currently living with her husband of 10 years and is desirous of a successful pregnancy.


Four years prior to consult in our institution, patient experienced heavy menstrual bleeding for 7 days, soaking 3 baby diapers per day with blood clots. She was assessed with abnormal uterine bleeding secondary to thickened endometrium and was admitted for blood transfusion. After 2 years, patient again had recurrence of heavy menstrual bleeding, this time associated with abdominal enlargement. Ultrasound was done and showed myoma uteri. She was again transfused with blood products and advised hysterectomy but patient refused due to financial constraints and desire of future fertility. Three months prior to consult in our institution, patient again experienced continuous vaginal bleeding, abdominal enlargement and pain with pallor and fatigue. She was rushed again to the same hospital and was admitted for blood transfusion and work up. On assessment, there was a polypoid mass occupying the vaginal canal and was sampled for biopsy. The histopathology result revealed atypical polypoid adenomyoma so the patient was referred to our institution.

On our initial examination, the patient was pale but with stable vital signs. Pelvic examination revealed a hemorrhagic polypoid fleshy mass occupying the whole vaginal canal that easily bleeds in manipulation measuring 6 cm x 6 cm (Figure 5). The cervix was difficult to assess and the corpus was enlarged to 20-22 weeks size. Rectovaginal examination was unremarkable.



Figure 5. Speculum examination of the patient prior to GnRH agonist.

Transvaginal ultrasound was done which showed an echogenic mass within the endometrial, endocervical and vaginal canal measuring 12.8cm x 12.2cm x 8.1cm with multiple irregular cystic spaces, invading >50% of the posterior myometrium (Figure 6). The impression was endocervical and endometrial masses consider atypical polyp with >50% myometrial invasion. Repeat biopsy of the prolapsed endometrial mass was done which revealed endometrial polyp.






Figure 6. Ultrasound of the endocervical and endometrial masses prior to GnRH agonist.

Patient was also referred to our section for possible hysteroscopic polypectomy. But again, due to the size of the mass and expected technical difficulty for hysteroscopic removal, pre-treatment with GnRH agonist prior to surgery was advised.

After 2 doses of GnRH, there was significant improvement of patient's symptoms with minimal vaginal bleeding, admixed with meat-like materials. On internal examination, the prolapsing endometrial mass within the vaginal canal decreased to 2cm x 2cm (Figure 7) and the corpus size decreased to 16-18 weeks from the initial 20-22 weeks size. Repeat ultrasound also noted a decrease in the size of the endometrial mass to 10.7cm x 11.8cm x 5.0cm (Figure 8). After the 3rd dose of the GnRH, the patient was re-assessed if additional GnRH is needed or if already amenable to hysteroscopic polypectomy.

Case 3

The last case is a 36-year-old, nulligravid who came in due to abdominal enlargement and intermenstrual bleeding. Patient has no comorbids but is unable to conceive for 9 years with her husband.

One year prior to consult, she began to develop inter-menstrual bleeding, soaking 3 pads per day lasting 1-2 days associated with abdominal enlargement. On pelvic examination, there is a 3cm x 3cm polypoid mass protruding out the endocervical canal, which seems to be coming from the endometrial cavity, the cervix is dilated by the said mass and the corpus is enlarged to




Figure 7. Speculum examination of the patient after 2 doses of GnRH agonist.




Figure 8. Repeat ultrasound of the patient after 2 doses of GnRH.

18-20 weeks size. Ultrasound showed an endometrial mass measuring 11.0cm x 8.2cm x 3.2cm with irregular cystic spaces and seems to be contiguous with the endocervical mass (Figure 9). Endometrial biopsy was done to rule out malignancy, and the result was endometrial polyp, hyperplastic type.

Management was again GnRH for 3 doses and re-assesed if amenable for hysteroscopy. After her 1st dose of GnRH, the size of the corpus significantly decreased to 14 to 16 weeks size. Patient also reported fragments passage of meatlike material with minimal vaginal bleeding. Repeat ultrasound was done and the size also significantly decreased to 7.5cm x 6.5cm x 6.1cm (Figure 10). Patient is still for completion of 2 more doses of GnRH prior to re-assessment.

Outcome and Follow up:

Endometrial polyp is one of the most common structural causes of abnormal uterine bleeding

CERVICAL MASS

Figure 9. Ultrasound of the endocervical and endometrial masses prior to GnRH agonist.

among the reproductive age group. It could present as intermenstrual or heavy menstrual bleeding and the amount of bleeding is usually proportional to the size of the endometrial polyp: the larger the size, the more debilitating to the patient. Aside from bleeding, it is also associated with infertility just as the cases presented.

Endometrial polyps are formed from localized overgrowths of endometrial tissue composed of variable amount of glands, stroma, and blood vessels covered by epithelium. The stroma of a polyp is composed of fibroblast like spindle cells and large blood vessels with thick walls. Commonly, the size of a polyp is less than 2 cm, however, polyps greater than 4 cm are called giant polyps, as shown in the cases above, whose sizes range from 10 to 12 cm. The development of endometrial polyps has been explained by a number of




Figure 10. Repeat ultrasound of the patient after 1 dose of GnRH.

molecular mechanisms such as monoclonal endometrial hyperplasia, over-expression of endometrial aromatase and gene mutations.² It usually arises because of estrogen hypersensitivity in some areas of the endometrium, probably caused by hyperactivation of the beta or the alpha estrogen receptor during the first phase of the cycle. Furthermore, they do not shed with menstruation because the estrogen related inflammation block the apoptosis via bcl-2 gene expression. Giant polyps, on the other hand are known to occur due to unbalanced estrogen levels. This estrogen related polyp growth occurs due to angiogenic growth factors' deregulation, produced under hormone control inside the polyp, within a short time and few cycles.4

Histopathological examination must be performed on all resected polyps to rule out endometrial polyps (0.5%-3%) with malignant foci. Lasmar BP, et al. reported that endometrial polyps larger than 15 mm are associated with hyperplasia and Wang J, et al. identified that polyps measuring more than 10 mm are associated with malignancy.² All 3 cases of giant polyps presented underwent endometrial biopsy to rule out the possibility of malignancy prior to choosing conservative treatment. Conservative was advocated since all 3 cases have issues with infertility and still in the reproductive age group where pregnancy is still likely.

For the management and histologic diagnosis of endometrial polyps, hysteroscopic resection is the preferred method.² However, in some instances like in giant polyps, immediate hysteroscopic removal may not be feasible. This could be due that giant polyps occupy the entire uterine cavity that distending the cavity during hysteroscopy for visualization of the polyp's attachment may not be done. Aside from failed removal of the polyp, morbidities like fluid overload and uterine perforation can be encountered. Although there is limited evidence with the use of GnRH agonist in endometrial polyps, its use was still suggested in the cases presented as it may possibly and significantly decrease the size of the polyps, as to make the hysteroscopic resection achievable.

GnRH agonists have revolutionized the management of many conditions in gynecology

based on the discovery that when administered in a non-pulsatile fashion, they down regulate pituitary GnRH receptors, and therefore decrease the production of FSH and LH. Several GnRH agonists are available for clinical use, and their potential use in myomas became apparent when it was realized that estrogen accelerate the growth of myomas.⁶ They were first tested as therapeutic treatments for myomas in the late 1980s when Filicori, et al. and Maheux, et al. demonstrated a reduction in the size of the myoma.⁶ However, there is limited data supporting GnRH agonist's utility for treating endometrial polyps.⁵

GnRH agonists have been widely used for submucus myomas to decrease its size and make its hysteroscopic removal manageable with less morbidity. It used as a neo-adjuvant therapy prior to hysteroscopy to decrease bulk of the myoma and induce a state of hypoestrogenism. Pretreatment with GnRH agonists improves the hemoglobin level, reduces blood loss during surgery, and reduces uterine and leiomyoma volumes in as much as 40-50%, with most of the reduction occurs in the first 12 weeks.⁷ This is especially helpful in infertile patients because this prevents destruction of the surrounding endometrial tissue.³

Given the same concept for myomas, GnRH can then be used as pre-treatment for giant polyps since they have characteristic cytogenetic rearrangements similar to uterine leiomyoma.² As mentioned earlier, polyps contain estrogen as well as progesterone receptors, and the concentrations of these receptors are significantly higher in the glandular epithelium of endometrial polyps than those in the normal endometrium.7 Hormonal inhibition of the endometrium can induce mucosal thinning and decreased bleeding. The effect of GnRH agonist can extend up to 1 month from the last dose and this could be due to persistent hypoestrogenism and consequent inhibition of regeneration of viable endometrial cells.⁵ In the cases presented, GnRH agonist has significantly decreased the size of giant polyps even after 1 dose. All of the patients have reported vaginal bleeding along with passage of meat-like materials, which were believed to be fragments of the polyp spontaneously sloughing off from its attachment

due to devascularizing effect of the GnRH agonist. None of the cases developed anemia or needed blood transfusion despite the said vaginal bleeding. The 1st case even successfully underwent hysteroscopic polypectomy after 6 doses of GnRH with no morbidity encountered and no residuals after, given the initial size of her polyp.

With this in mind, there is room for GnRH agonists in treating endometrial polyps, specifically the giant polyps, where immediate hysteroscopic removal may tend to be difficult or may lead to failure, more so morbidity. The cases have shown the effect of GnRH agonists in significantly decreasing the size of the polyps probably by inducing a hypoestrogenic state and at the same time deceasing the vascularization of the polyps causing it to spontaneously slough off from its base. This will facilitate complete hysteroscopic removal of the giant polyp at the same time decreasing chances of morbidity. Although further studies are needed to strengthen its use in endometrial polyps, this may open an area for more research work.

References

- 1. Nigel Pereira AC, Petrini JP, Lekovich R, Elias T, Spandorfer SD. Surgical management of endometrial polyps in infertile women: A comprehensive review. Surg Res Pract 2015: 914390.
- 2. Tyagi S, Manchanda R, Kulkarni S, Samadi F. Manchanda's Endoscopic Centre, PSRI Hospital, New Delhi. Giant endometrial polyps - A case series. Int J Curr Adv Res 2017; 6(6): 4185-9.
- 3. Romer T. Benefit of GnRH analogue pretreatment for hysteroscopic surgery in patients with bleeding disorders. Gynecol Obstet Invest 1998; 45(suppl 1): 12-21.
- 4. Ugo I, Matteo M, Di Iorio R. The pathogenesis of endometrial polyps: A systematic semi-quantitative review. Int J Clin Med 2011; 2: 478-80.
- 5. Vercellini P, Trespidi L, Bramante T, Panazza S, Mauro F, Crosignani PG. Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection. Int Fed Gynecol Obstet 1994; 45: 235-9.
- 6. Talaulikar VS, Belli AM, Manyonda I. GnRH agonists: Do they have a place in the modern management of fibroid disease? J Obstet Gynaecol India 2012; 62(5): 506-10.
- 7. Lin YH, Chou YY, Huang LW, Seow KM, Hwang JL. An adenomyomatous polyp presenting as a large hypervascular tumor and its response to a gonadotropinreleasing hormone agonist. Taiwanese J Obstet Gynecol 2013; 52: 129e130